Literature DB >> 23234288

Cutaneous neoplastic lesions of equids in the central United States and Canada: 3,351 biopsy specimens from 3,272 equids (2000-2010).

Paula A Schaffer1, Bruce Wobeser, Laura E R Martin, Michelle M Dennis, Colleen G Duncan.   

Abstract

OBJECTIVE: To identify epidemiological trends in cutaneous neoplasms affecting equids in central North America and compare them with previously reported trends.
DESIGN: Retrospective case series. SAMPLE: 3,351 cutaneous biopsy specimens from 3,272 equids with a neoplastic diagnosis. PROCEDURES: Diagnostic reports from 2 diagnostic laboratories (Colorado State University and Prairie Diagnostic Services Inc) were reviewed for frequency of specific lesions and epidemiological trends. Variables included in analyses (if known) were age, sex, breed, geographic location, date of diagnosis, location of neoplasm on the body, and presence or absence of ulceration.
RESULTS: Sarcoid, squamous cell carcinoma (SCC), and melanoma were the 3 most common tumors diagnosed. Tumors associated with UV radiation (SCC, SCC in situ, hemangioma, hemangiosarcoma) were 2.3 (95% confidence interval [CI], 1.8 to 3.0) times as common in biopsy specimens received by Colorado State University than in specimens received by Prairie Diagnostic Services Inc. Appaloosa horses and American Paint horses, respectively, were 7.2 (95% CI, 5.6 to 9.2) and 4.4 (95% CI, 3.6 to 5.4) times as likely as other breeds to have tumors associated with UV radiation. Thoroughbreds were predisposed to cutaneous lymphoma, whereas Arabians were more likely to have melanomas. Draft and pony breeds were 3.1 (95% CI, 1.9 to 5.1) times as likely as other breeds to have benign soft tissue tumors. Morgans and pony breeds more commonly had basal cell tumors. Tumors in the perianal region were significantly more likely to be SCC or melanoma while tumors on the limbs were more likely to be giant cell tumor of soft parts. CONCLUSIONS AND CLINICAL RELEVANCE: Signalment, anatomic location of the mass, and geographic location of the horse can be used to help equine practitioners formulate differential diagnoses for cutaneous masses. Further research is necessary to identify the biological basis for the development of many equine cutaneous neoplasms.

Entities:  

Mesh:

Year:  2013        PMID: 23234288     DOI: 10.2460/javma.242.1.99

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  9 in total

1.  Non-neoplastic lesions of equine skin in the central United States and Canada: a retrospective study.

Authors:  Paula A Schaffer; Bruce Wobeser; Michelle M Dennis; Colleen G Duncan
Journal:  Can Vet J       Date:  2013-03       Impact factor: 1.008

2.  The potential of three whole blood microRNAs to predict outcome and monitor treatment response in sarcoid-bearing equids.

Authors:  E Hamza; J Cosandey; V Gerber; C Koch; L Unger
Journal:  Vet Res Commun       Date:  2022-04-28       Impact factor: 2.459

3.  Differences in miRNA differential expression in whole blood between horses with sarcoid regression and progression.

Authors:  Lucia Unger; Vidhya Jagannathan; Alicja Pacholewska; Tosso Leeb; Vinzenz Gerber
Journal:  J Vet Intern Med       Date:  2018-12-02       Impact factor: 3.333

4.  Additional Evidence for DDB2 T338M as a Genetic Risk Factor for Ocular Squamous Cell Carcinoma in Horses.

Authors:  Moriel H Singer-Berk; Kelly E Knickelbein; Zachary T Lounsberry; Margo Crausaz; Savanna Vig; Nikhil Joshi; Monica Britton; Matthew L Settles; Christopher M Reilly; Ellison Bentley; Catherine Nunnery; Ann Dwyer; Mary E Lassaline; Rebecca R Bellone
Journal:  Int J Genomics       Date:  2019-09-15       Impact factor: 2.326

5.  DDB2 Genetic Risk Factor for Ocular Squamous Cell Carcinoma Identified in Three Additional Horse Breeds.

Authors:  Margo Crausaz; Thomas Launois; Kathryn Smith-Fleming; Annette M McCoy; Kelly E Knickelbein; Rebecca R Bellone
Journal:  Genes (Basel)       Date:  2020-12-05       Impact factor: 4.096

6.  DNA methylation aging and transcriptomic studies in horses.

Authors:  Steve Horvath; Amin Haghani; Sichong Peng; Erin N Hales; Joseph A Zoller; Ken Raj; Brenda Larison; Todd R Robeck; Jessica L Petersen; Rebecca R Bellone; Carrie J Finno
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 14.919

7.  ALVAC-fIL2, a feline interleukin-2 immunomodulator, as a treatment for sarcoids in horses: A pilot study.

Authors:  Corey Saba; Randall Eggleston; Andrew Parks; John Peroni; Eric Sjoberg; Shelbe Rice; Jesse Tyma; Jarred Williams; Deborah Grosenbaugh; A Timothy Leard
Journal:  J Vet Intern Med       Date:  2022-04-13       Impact factor: 3.175

8.  Expression of Cell-Cycle Regulatory Proteins pRb, Cyclin D1, and p53 Is Not Associated with Recurrence Rates of Equine Sarcoids.

Authors:  Giorgia Tura; Barbara Brunetti; Elena Brigandì; Riccardo Rinnovati; Giuseppe Sarli; Giancarlo Avallone; Luisa Vera Muscatello; Roberto Marcello La Ragione; Andy E Durham; Barbara Bacci
Journal:  Vet Sci       Date:  2022-09-01

9.  Diagnostic and prognostic potential of eight whole blood microRNAs for equine sarcoid disease.

Authors:  Jeanne Cosandey; Eman Hamza; Vinzenz Gerber; Alessandra Ramseyer; Tosso Leeb; Vidhya Jagannathan; Klaudia Blaszczyk; Lucia Unger
Journal:  PLoS One       Date:  2021-12-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.